Medical Condition News

RSS

Online community launched to help families affected by PTSD

Since the Vietnam Era, the American psychiatric community has recognized the returning war veterans’ affliction of what is now commonly known as Post Traumatic Stress Disorder (PTSD).

11 Nov 2009

Women face higher risk of post-stroke depression

Depression occurs in as many as one-third of patients after a stroke, and women are at somewhat higher risk, according to a large new review of studies. Post-stroke depression is associated with greater disability, reduced quality of life and an increased risk of death.

11 Nov 2009

New mapping technology to treat patients with heart rhythm disorders

Physicians with California Pacific Medical Center are among the first in the nation to use a new advanced mapping technology to help treat patients suffering from debilitating and potentially dangerous heart rhythm disorders.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

Pfizer and BMP Sunstone team up to promote Depo-Provera, a product for treating endometriosis

Pfizer China and BMP Sunstone Corporation today announced a strategic partnership to exclusively import, distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China. Endometriosis is a medical condition in women of childbearing age that can cause significant pain.

11 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

Chronic kidney disease on the rise; preventive testing is critical for diabetic patients

New data confirms the rate of chronic kidney disease is inching upward, keeping pace with the rising rates of diabetes. In late September, the U.S. Renal Data System published its 2009 Annual Data report, which shows the incidence of chronic kidney disease in the U.S. Medicare population is now 9.8%, up from 8.7% reported in last year’s data analysis.

11 Nov 2009

Researchers identify cause that leads to age-related hearing loss

Age-related hearing loss is the most common sensory disorder among the elderly. But scientists are still trying to figure out what cellular processes govern or contribute to the loss.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

Children with autism have slower pupil responses to light change: Study

Autism affects 1 in 150 children today, making it more common than childhood cancer, juvenile diabetes and pediatric AIDS combined. Despite its widespread effect, autism is not well understood and there are no objective medical tests to diagnose it. Recently, University of Missouri researchers have developed a pupil response test that is 92.5 percent accurate in separating children with autism from those with typical development. In the study, MU scientists found that children with autism have slower pupil responses to light change.

11 Nov 2009

Occupational contact dermatitis and asthma are most common work-related health issues, says new research

Occupational contact dermatitis and asthma are two of the most common work-related health issues facing workers worldwide, according to experts presenting the latest research at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

11 Nov 2009

New educational program for caregivers of patients with Lennox-Gastaut syndrome

Eisai Inc. introduced a new educational program today to help parents and caregivers of patients with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy in which patients have frequent seizures of multiple types.

11 Nov 2009

GORE TAG Thoracic Endoprosthesis receives European CE Mark approval

W.L. Gore & Associates (Gore) today announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. The device is available in an expanded portfolio of sizes to meet a broad range of patient needs and was engineered to treat multiple etiologies including thoracic aortic aneurysms (TAAs), traumatic aortic transections and thoracic aortic dissections.

11 Nov 2009

Texting linked to pain in neck and shoulders among college students

The world record for fastest text message typing is held by a 21-year old college student from Utah, but his dexterous digits could mean serious injury later on. Most adults aged 18-21 prefer texting over e-mail or phone calls, and ergonomics researchers are starting to wonder whether it's putting the younger generation at risk for some overuse injuries - once reserved for older adults who have spent years in front of a computer.

10 Nov 2009

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Medical Condition News

Online community launched to help families affected by PTSD

Women face higher risk of post-stroke depression

New mapping technology to treat patients with heart rhythm disorders

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Pfizer and BMP Sunstone team up to promote Depo-Provera, a product for treating endometriosis

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Chronic kidney disease on the rise; preventive testing is critical for diabetic patients

Researchers identify cause that leads to age-related hearing loss

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Potential new drug for lung cancer eliminates tumors in mice

Children with autism have slower pupil responses to light change: Study

Occupational contact dermatitis and asthma are most common work-related health issues, says new research

New educational program for caregivers of patients with Lennox-Gastaut syndrome

GORE TAG Thoracic Endoprosthesis receives European CE Mark approval

Texting linked to pain in neck and shoulders among college students

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

BioVex completes $70M financing to complete OncoVEX Phase III study

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News